The Blood Screening Market is undergoing a technology transformation as blood centers increasingly adopt molecular testing, multiplex platforms, and next-generation sequencing. Market Research Future projects the market to grow at a 9.0% CAGR through 2035, with technological innovation becoming an important source of future demand.

Nucleic acid amplification testing currently leads the technology landscape, accounting for approximately 45% of market revenue in 2025. Its importance reflects the growing use of molecular approaches for identifying infectious agents in donated blood and strengthening screening capabilities.

Next-generation sequencing is emerging as another important technology area. The segment is projected to expand at an 11.9% CAGR through 2035, supported by its potential role in detecting variants and identifying pathogens beyond conventional targeted screening panels. This could make NGS increasingly relevant to pathogen surveillance and future blood-safety strategies.

Immunoassay technologies continue to have an important complementary role, particularly in high-volume screening and blood-group-related testing. Rapid testing also remains relevant in regions where centralized molecular infrastructure is still developing, creating a diverse technology landscape across global markets.

Future technology development is likely to emphasize multiplexing, automation, artificial intelligence, and integration between screening and other blood-safety processes. Vendors that can combine high throughput with flexible testing menus and digital connectivity may gain a stronger position as blood centers modernize their technology infrastructure.

Gain a competitive edge with insightful market reports:

Chronic Disease Management Market Size

Chronic Disease Management Market Share

Chronic Disease Management Market Trends

Chronic Disease Management Market Growth

Chronic Disease Management Market Demand